Main menu

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced the acquisition of a portfolio of six patents and applications related to tissue microarrays for an undisclosed amount.

Nuclea acquired the IP from Laurus Master Fund, a division of Laurus Capital Management. Clinomics Biosciences previously owned the IP and assigned it to Laurus, but since then, the patents have not been maintained, Nuclea said, adding that it plans to petition the US Patent and Trademark Office immediately to revive them.